Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 4Gastrointestinal Neoplasms 2Bile Duct Neoplasms 2Vulvar Neoplasms 1Sarcoma 1Prostatic Neoplasms 1Ovarian Neoplasms 1Neuroendocrine Tumors 1Liver Neoplasms 1Hereditary Sensory and Autonomic Neuropathies 1Gallbladder Neoplasms 1Cholangiocarcinoma 1Carcinoma, Neuroendocrine 1Carcinoma, Hepatocellular 1Breast Neoplasms 1Advanced Adult Hepatocellular Carcinoma 1

Interventions

Cetuximab 5Irinotecan 3Gemcitabine 2tivozanib 1neratinib 1lorlatinib 1liposomal doxorubicin 1encorafenib 1binimetinib 1Taxes 1Secretin 1Paclitaxel 1PX-866 1Oxaliplatin 1Lomustine 1Leucovorin 1Fluorouracil 1Doxorubicin 1Carboplatin 1Capecitabine 1CB-839 1CA-19-9 Antigen 1Bevacizumab 1Aspirin 1Albumin-Bound Paclitaxel 13-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hereditary Sensory and Autonomic Neuropathies × tivozanib × Gastrointestinal × Clear all
NCT04645160 2026-06-03

Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract Cancers

National Institutes of Health Clinical Center (CC)

Phase 1/2 Recruiting
31 enrolled
Gastrointestinal

Bile Duct Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡